Switch theme
Sign up to access all valuation multiples
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
2021
52
LTM Revenue $2.1M
LTM EBITDA -$107M
$67.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Upstream Bio has a last 12-month revenue (LTM) of $2.1M and a last 12-month EBITDA of -$107M.
In the most recent fiscal year, Upstream Bio achieved revenue of $2.4M and an EBITDA of -$77.7M.
Upstream Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Upstream Bio valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.1M | XXX | $2.4M | XXX | XXX | XXX |
| Gross Profit | $2.1M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$107M | XXX | -$77.7M | XXX | XXX | XXX |
| EBITDA Margin | -5215% | XXX | -3277% | XXX | XXX | XXX |
| EBIT | -$108M | XXX | -$77.8M | XXX | XXX | XXX |
| EBIT Margin | -5226% | XXX | -3281% | XXX | XXX | XXX |
| Net Profit | -$94.3M | XXX | -$62.8M | XXX | XXX | XXX |
| Net Margin | -4575% | XXX | -2650% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Upstream Bio's stock price is $9.
Upstream Bio has current market cap of $498M, and EV of $67.9M.
See Upstream Bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $67.9M | $498M | XXX | XXX | XXX | XXX | $-4.33 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Upstream Bio has market cap of $498M and EV of $67.9M.
Upstream Bio's trades at 28.7x EV/Revenue multiple, and -0.9x EV/EBITDA.
Equity research analysts estimate Upstream Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Upstream Bio has a P/E ratio of -5.3x.
See valuation multiples for Upstream Bio and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $498M | XXX | $498M | XXX | XXX | XXX |
| EV (current) | $67.9M | XXX | $67.9M | XXX | XXX | XXX |
| EV/Revenue | 33.0x | XXX | 28.7x | XXX | XXX | XXX |
| EV/EBITDA | -0.6x | XXX | -0.9x | XXX | XXX | XXX |
| EV/EBIT | -0.6x | XXX | -0.9x | XXX | XXX | XXX |
| EV/Gross Profit | 33.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.3x | XXX | -7.9x | XXX | XXX | XXX |
| EV/FCF | -1.5x | XXX | -1.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialUpstream Bio's last 12 month revenue growth is -27%
Upstream Bio's revenue per employee in the last FY averaged $46K, while opex per employee averaged $1.5M for the same period.
Upstream Bio's rule of 40 is -1710% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Upstream Bio's rule of X is -5282% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Upstream Bio and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -27% | XXX | -24% | XXX | XXX | XXX |
| EBITDA Margin | -5215% | XXX | -3277% | XXX | XXX | XXX |
| EBITDA Growth | 47% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -1710% | XXX | -3304% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -5282% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $46K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2657% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 3381% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Upstream Bio acquired XXX companies to date.
Last acquisition by Upstream Bio was XXXXXXXX, XXXXX XXXXX XXXXXX . Upstream Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Upstream Bio founded? | Upstream Bio was founded in 2021. |
| Where is Upstream Bio headquartered? | Upstream Bio is headquartered in United States of America. |
| How many employees does Upstream Bio have? | As of today, Upstream Bio has 52 employees. |
| Who is the CEO of Upstream Bio? | Upstream Bio's CEO is Dr. Everett Rand Sutherland, M.D.. |
| Is Upstream Bio publicy listed? | Yes, Upstream Bio is a public company listed on NAS. |
| What is the stock symbol of Upstream Bio? | Upstream Bio trades under UPB ticker. |
| When did Upstream Bio go public? | Upstream Bio went public in 2024. |
| Who are competitors of Upstream Bio? | Similar companies to Upstream Bio include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Upstream Bio? | Upstream Bio's current market cap is $498M |
| What is the current revenue of Upstream Bio? | Upstream Bio's last 12 months revenue is $2.1M. |
| What is the current revenue growth of Upstream Bio? | Upstream Bio revenue growth (NTM/LTM) is -27%. |
| What is the current EV/Revenue multiple of Upstream Bio? | Current revenue multiple of Upstream Bio is 33.0x. |
| Is Upstream Bio profitable? | Yes, Upstream Bio is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Upstream Bio? | Upstream Bio's last 12 months EBITDA is -$107M. |
| What is Upstream Bio's EBITDA margin? | Upstream Bio's last 12 months EBITDA margin is -5215%. |
| What is the current EV/EBITDA multiple of Upstream Bio? | Current EBITDA multiple of Upstream Bio is -0.6x. |
| What is the current FCF of Upstream Bio? | Upstream Bio's last 12 months FCF is -$45.4M. |
| What is Upstream Bio's FCF margin? | Upstream Bio's last 12 months FCF margin is -2204%. |
| What is the current EV/FCF multiple of Upstream Bio? | Current FCF multiple of Upstream Bio is -1.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
